Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia

Drugs

Volumn 72, Issue 11, 2012, Pages 1445-1455

  Gelsinger, Carmen ^a   Steinhagen Thiessen, Elisabeth ^a   Kassner, Ursula ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Apheresis; Hyperlipoproteinaemia type IIa; LDL cholesterol; Lipoprotein a; Mipomersen sodium

Indexed keywords

ANTILIPEMIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADD ON THERAPY; ARTICLE; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; FATIGUE; FATTY LIVER; FEVER; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPERLIPIDEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; MONOTHERAPY; MYALGIA; NAUSEA; NONHUMAN; PHARMACODYNAMICS; RHINOPHARYNGITIS; SIDE EFFECT; STEATORRHEA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DOUBLE-BLIND METHOD; DRUG EVALUATION, PRECLINICAL; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEIN(A); OLIGONUCLEOTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIGLYCERIDES;

EID: 84864239186     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635060-000000000-00000     Document Type: Article

References (74)

1. Lamon-Fava S, Marcovina SM, Albers JJ, et al. Lipoprotein( a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res 2011 Jun; 52 (6): 1181-7
2. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010 Dec; 31 (23): 2844-53
3. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation 2007 Oct 16; 116 (16): 1832-44 (Pubitemid 350287108)
4. Identification and management of familial hypercholesterolaemia (FH).-NCBI Bookshelf [online]. Available from URL: http://www.ncbi.nlm.nih.gov/ books/NBK53822/ [Accessed 2012 Mar 18]
5. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423
6. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 Oct 8; 366 (9493): 1267-78
7. Elis A, Zhou R, Stein EA. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades. Am J Cardiol 2011 July 15; 108 (2): 223-6
8. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005 Nov 16; 294 (19): 2437-45 (Pubitemid 41627921)
9. Pedersen TR, Cater NB, Faergeman O, et al. Comparison of atorvastatin 80 mg/day versus simvastatin 20 to 40mg/day on frequency of cardiovascular events late (five years) after acute myocardial infarction (from the Incremental Decrease in End Points through Aggressive Lipid Lowering [IDEAL] trial). Am J Cardiol 2010 Aug 1; 106 (3): 354-9
10. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011 July; 217 Suppl. 1: S1-44
11. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004 July 13; 110 (2): 227-39 (Pubitemid 38924592)
12. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986 Apr 4; 232 (4746): 34-47 (Pubitemid 16037973)
13. Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004 Sep 1; 160 (5): 407-20 (Pubitemid 39166973)
14. WeisgraberKH, Innerarity TL,NewhouseYM, et al. Familialdefective apolipoprotein B-100: enhanced binding of monoclonal antibodyMB47 to abnormal low density lipoproteins. Proc Natl Acad Sci U S A 1988 Dec; 85 (24): 9758-62 (Pubitemid 19027204)
15. McGowan M. NLA Symposium screening and treatment of familial hypercholesterolemia: how can we do better? Opening and introductions. J Clin Lipidol 2010 Oct; 4 (5): 335-7
16. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol 2009 Apr; 29 (4): 431-8
17. No authors listed. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999 Jan; 142 (1): 105-12
18. Scriver CR, Beaudet AL, Sly WS. The metabolic and molecular basis of inherited disease. 8th ed. New York: Mcgraw-Hill, 2001
19. Weng T-C, Yang Y-HK, Lin S-J, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010 Apr; 35 (2): 139-51
20. Armitage J. The safety of statins in clinical practice. Lancet 2007 Nov 24; 370 (9601): 1781-90 (Pubitemid 350137473)
21. Neil HAW, Hammond T, Mant D, et al. Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002. BMJ 2004 Feb 28; 328 (7438): 500-1 (Pubitemid 38293611)
22. Huijgen R, Kindt I, Verhoeven SBJ, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS ONE 2010; 5 (2): e9220
23. Umans-Eckenhausen MAW, Defesche JC, van Dam MJ, et al. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med 2003 Jan 13; 163 (1): 65-8 (Pubitemid 36091602)
24. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010 Feb; 208 (2): 317-21
25. Nenseter MS, Lindvig HW, Ueland T, et al. Lipoprotein(a) levels in coronary heart disease-susceptible and -resistant patients with familial hypercholesterolemia. Atherosclerosis 2011 June; 216 (2): 426-32
26. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009 Dec 24; 361 (26): 2518-28
27. Keller C. Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management. Ther Apher Dial 2007 Feb; 11 (1): 2-8
28. Kassner U, Vogt A, Rosada A, et al. Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a). Atheroscler Suppl 2009 Dec 29; 10 (5): 85-8
29. Utermann G, Hoppichler F, Dieplinger H, et al. Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci U S A 1989 June; 86 (11): 4171-4 (Pubitemid 19154756)
30. Holmes DT, Schick BA, Humphries KH, et al. Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem 2005 Nov; 51 (11): 2067-73 (Pubitemid 41532622)
31. Jansen ACM, van Aalst-Cohen ES, Tanck MW, et al. The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med 2004 Dec; 256 (6): 482-90 (Pubitemid 39577582)
32. Akdim F, Stroes ESG, Kastelein JJP. Antisense apolipoprotein B therapy: where do we stand? Curr Opin Lipidol 2007 Aug; 18 (4): 397-400 (Pubitemid 47051917)
33. Crooke ST. Progress in antisense technology. Annu Rev Med 2004; 55: 61-95 (Pubitemid 38316716)
34. Crooke RM, Graham MJ, Lemonidis KM, et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005 May; 46 (5): 872-84
35. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004 Nov 11; 432 (7014): 173-8 (Pubitemid 39545841)
36. Yu RZ, Kim T-W, Hong A, et al. Cross-species pharmacokinetic comparison from mouse to man of a secondgeneration antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 2007 March; 35 (3): 460-8 (Pubitemid 46333910)
37. Goldberg AC. Novel therapies and new targets of treatment for familial hypercholesterolemia. J Clin Lipidol 2010 Oct; 4 (5): 350-6
38. Crooke RM. Antisense oligonucleotides as therapeutics for hyperlipidaemias. Expert Opin Biol Ther 2005 July; 5 (7): 907-17 (Pubitemid 41032848)
39. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999 Oct; 246 (4): 341-55 (Pubitemid 29479916)
40. ChapmanMJ, Ginsberg HN, Amarenco P, et al. Triglyceriderich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J [online]. Available from URL: http://eurheartj.oxfordjournals.org/content/ early/2011/04/29/eurheartj.ehr112.abstract 2011 Apr 29 [Accessed 2011 Jun 17]
41. Young SG. Recent progress in understanding apolipoprotein B. Circulation 1990 Nov; 82 (5): 1574-94 (Pubitemid 20367961)
42. Dashti N, Gandhi M, Liu X, et al. The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly. Biochemistry 2002 June 4; 41 (22): 6978-87 (Pubitemid 34575669)
43. Bell DA, Hooper AJ, Burnett JR. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. Expert Opin Investig Drugs 2011 Feb; 20 (2): 265-72
44. DavidsonNO, ShelnessGS. APOLIPOPROTEIN B:mRNA editing, lipoprotein assembly, and presecretory degradation. Annu Rev Nutr 2000; 20: 169-93
45. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl JMed 2007 Jan 11; 356 (2): 148-56 (Pubitemid 46089675)
46. Brunton L, Chabner BA, Knollman B. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: Mcgraw-Hill Professional, 2011
47. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-93
48. Mullick AE, Fu W, Graham MJ, et al. Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice. J. Lipid Res 2011 May; 52 (5): 885-96
49. Koller E, Gaarde WA, Monia BP. Elucidating cell signaling mechanisms using antisense technology. Trends Pharmacol Sci 2000 Apr; 21 (4): 142-8 (Pubitemid 30190139)
50. Kastelein JJP, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006 Oct 17; 114 (16): 1729-35 (Pubitemid 44607121)
51. McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem 1999 Jan 15; 274 (3): 1715-22
52. Yu RZ, Zhang H, Geary RS, et al. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice. J Pharmacol Exp Ther 2001 Feb; 296 (2): 388-95 (Pubitemid 32112464)
53. No authors listed. Mipomersen. Am J Cardiovasc Drugs 2010; 10 (4): 271-9
54. Yu RZ, Lemonidis KM, Graham MJ, et al. Cross-species comparison of in vivo PK/PD relationships for secondgeneration antisense oligonucleotides targeting apolipoprotein B-100. Biochem Pharmacol 2009 March 1; 77 (5): 910-9
55. Akdim F, Tribble DL, Flaim JD, et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-tomoderate hyperlipidaemia. Eur Heart J. Epub 2011 May 18 [online]. Available from URL: http://eurheartj.oxfordjour nals.org/content/early/2011/05/18/eurheartj.ehr148.abstract [Accessed 2011 Aug 17]
56. Yu RZ, Geary RS, Flaim JD, et al. Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-Omethoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Clin Pharmacokinet 2009; 48 (1): 39-50
57. Isis® Pharmaceuticals. Genzyme and Isis announce submission of European Marketing Authorization Application for mipomersen (Kynamro®) [media release; online]. Available from URL: http://ir.isispharm.com/phoenix. zhtml?c=222170&p=irol-newsArticle&ID=1589917&highlight = [Accessed 2011 Oct 27]
58. Isis® Pharmaceuticals. Isis reports financial results and highlights for 2011 [media release]. 2012 Feb 29 [online]. Available from URL: http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID= 1667143&highlight = [Accessed 2012 Jul 1]
59. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, doubleblind, placebo-controlled trial. Lancet 2010 Mar 20; 375 (9719): 998-1006
60. Akdim F, Stroes ESG, Sijbrands EJG, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010 Apr 13; 55 (15): 1611-8
61. AkdimF,VisserME, TribbleDL, et al. Effect ofmipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010 May 15; 105 (10): 1413-9
62. Isis® Pharmaceuticals. Mipomersen data presented at European Atherosclerosis Society Congress: phase 3 studies highlight investigational drug's potential in lowering La(a) and reducing necessity for lipid-apheresis [media release] 2011 Jun 28 [online]. Available from URL: http://ir.isispharm. com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=1580350&highlight= [Accessed 2011 Oct 28]
63. Parhofer KG, Vogt A. Mipomersen, an apoB synthesis inhibitor, evaluation of potential to reduce necessity for lipidapheresis in patients with heterozygous FH and CAD [poster 4.114]. Poster presentation at the 79th EAS Congress; 2011 Jun 26-29; Gotenburg [online]. Available from URL: http://www.biotechduediligence.com/uploads/6/3/6/7/6367956/request-2011-06- presentations-eas.pdf [Accessed 2011 Oct 27]
64. Steingagen-Thiessen, Witztum JL, Tsimikas S, et al. Effect of mipomersen on Lp(a) in patients with heterozygous familial hypercholesterolemia; results from two phase 3 studies [poster 4.117]. Poster presentation at the 79th EAS Congress; 2011 Jun 26-29; Gotenburg [online]. Available from URL: http://www.biotechduediligence.com/uploads/6/3/6/7/6367956/request-2011-06- presentations-eas.pdf[Accessed 2011 Oct 27]
65. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012 May; 33 (9): 1142-9
66. Visser ME, Akdim F, Tribble DL, et al. Effect of apolipoprotein- B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res 2010 May; 51 (5): 1057-62
67. Genzyme, Isis Pharmaceuticals. Measure liver fat content after ISIS 301012 (Mipomersen) administration [Clinical- Trials.gov identifier NCT00362180]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2011 Oct 27]
68. National Institute for Health Research. Horizon Scanning Centre. Mipomersen for familial hypercholesterolemia: third or fourth line [online]. Available from URL: http://nhsc-healthhorizons.org.uk/topics/mipomersen-for- familialhypercholesterolemia-third/ [Accessed 2011 Oct 28]
69. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol 1995 May; 15 (5): 678-82
70. Stein E, Dufour R, Gagne C, et al. A randomized, doubleblind, placebo-controlled study to assess efficacy and safety of mipomersen as add-on-therapy in herterozygous familial hyoercholesterolemia patients with coronary artery disease [abstract]. Eur Heart J 2010; 31 Suppl. 1
71. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004 Mar 3; 291 (9): 1071-80 (Pubitemid 38541684)
72. Scheen AJ. Treating to new targets: plea for a LDL cholesterol target of or below 75mg/dl in any patient with coronary heart disease. Rev Med Liege 2005 Apr; 60 (4): 264-7 (Pubitemid 40712409)
73. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very highintensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006 Apr 5; 295 (13): 1556-65
74. Parhofer KG, Vogt A. 760 mipomersen and apoB synthesis inhibitor evaluation of potential to reduce necessity for lipid-apheresis in patients with heterozygous FH and CAD. Atherosclerosis 2011; 12 (1): 159